Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016, Article ID 4287158, 15 pages
http://dx.doi.org/10.1155/2016/4287158
Review Article

Young at Heart: Pioneering Approaches to Model Nonischaemic Cardiomyopathy with Induced Pluripotent Stem Cells

1Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino-IRCCS, Via Parea 4, 20138 Milan, Italy
2Department of Electronics, Information and Bioengineering, Politecnico di Milano, Piazza Leonardo da Vinci 32, Building No. 21, 20133 Milan, Italy
3Department of Clinical Sciences and Community Health, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy
4Cardiology Unit, San Gerardo Hospital, Via Giambattista Pergolesi 33, 20052 Monza, Italy
5Department of Cardiac Surgery, Centro Cardiologico Monzino-IRCCS, Via Parea 4, 20138 Milan, Italy

Received 27 November 2015; Accepted 9 February 2016

Academic Editor: Gary E. Lyons

Copyright © 2016 Aoife Gowran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. J. Maron, J. A. Towbin, G. Thiene et al., “Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention,” Circulation, vol. 113, no. 14, pp. 1807–1816, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Follath, “Nonischemic heart failure: epidemiology, pathophysiology and progression of disease,” Journal of Cardiovascular Pharmacology, vol. 33, supplement 3, pp. S31–S35, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. D. A. Bluemke, “MRI of nonischemic cardiomyopathy,” American Journal of Roentgenology, vol. 195, no. 4, pp. 935–940, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Franciosa, M. Wilen, S. Ziesche, and J. N. Cohn, “Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy,” The American Journal of Cardiology, vol. 51, no. 5, pp. 831–836, 1983. View at Publisher · View at Google Scholar · View at Scopus
  5. B. A. Bart, L. K. Shaw, C. B. McCants Jr. et al., “Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy,” Journal of the American College of Cardiology, vol. 30, no. 4, pp. 1002–1008, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Follath, “Ischemic versus non-ischemic heart failure: should the etiology be determined?” Heart Failure Monitor, vol. 1, no. 4, pp. 122–125, 2001. View at Google Scholar · View at Scopus
  7. B. F. Uretsky, J. B. Young, F. E. Shahidi, L. G. Yellen, M. C. Harrison, and M. K. Jolly, “Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial,” Journal of the American College of Cardiology, vol. 22, no. 4, pp. 955–962, 1993. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Packer, M. Gheorghiade, J. B. Young et al., “Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors,” The New England Journal of Medicine, vol. 329, no. 1, pp. 1–7, 1993. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Malliaras, R. R. Makkar, R. R. Smith et al., “Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-derived aUtologous stem CElls to reverse ventricular dysfunction),” Journal of the American College of Cardiology, vol. 63, no. 2, pp. 110–122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Tendera, W. Wojakowski, W. Ruyłło et al., “Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: Results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) trial,” European Heart Journal, vol. 30, no. 11, pp. 1313–1321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. A. Fisher, D. M. Clifford, S. J. Brunskill et al., “Stem cell treatment for acute myocardial infarction,” The Cochrane Database of Systematic Reviews, vol. 9, Article ID CD006536, 2015. View at Publisher · View at Google Scholar
  12. M. Peruzzi, E. De Falco, A. Abbate et al., “State of the art on the evidence base in cardiac regenerative therapy: overview of 41 systematic reviews,” BioMed Research International, vol. 2015, Article ID 613782, 7 pages, 2015. View at Publisher · View at Google Scholar
  13. S. Maltais, S. J. Joggerst, A. Hatzopoulos et al., “Stem cell therapy for chronic heart failure: an updated appraisal,” Expert Opinion on Biological Therapy, vol. 13, no. 4, pp. 503–516, 2013. View at Publisher · View at Google Scholar
  14. J. A. Thomson, “Embryonic stem cell lines derived from human blastocysts,” Science, vol. 282, no. 5391, pp. 1145–1147, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. R. Braam, L. Tertoolen, A. van de Stolpe, T. Meyer, R. Passier, and C. L. Mummery, “Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes,” Stem Cell Research, vol. 4, no. 2, pp. 107–116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Guo, R. M. C. Abrams, J. E. Babiarz et al., “Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes,” Toxicological Sciences, vol. 123, no. 1, pp. 281–289, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Harris, M. Aylott, Y. Cui, J. B. Louttit, N. C. McMahon, and A. Sridhar, “Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays,” Toxicological Sciences, vol. 134, no. 2, pp. 412–426, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. P. W. Burridge, S. Diecke, E. Matsa, A. Sharma, H. Wu, and J. C. Wu, “Modeling cardiovascular diseases with patient-specific human pluripotent stem cell-derived cardiomyocytes,” Methods in Molecular Biology, vol. 1353, pp. 119–130, 2016. View at Publisher · View at Google Scholar
  20. H. Fonoudi, H. Ansari, S. Abbasalizadeh et al., “A universal and robust integrated platform for the scalable production of human cardiomyocytes from pluripotent stem cells,” Stem Cells Translational Medicine, vol. 4, no. 12, pp. 1482–1494, 2015. View at Publisher · View at Google Scholar
  21. D. Qin, Y. Xia, and G. M. Whitesides, “Soft lithography for micro- and nanoscale patterning,” Nature Protocols, vol. 5, no. 3, pp. 491–502, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Boudou, W. R. Legant, A. Mu et al., “A microfabricated platform to measure and manipulate the mechanics of engineered cardiac microtissues,” Tissue Engineering Part A, vol. 18, no. 9-10, pp. 910–919, 2012. View at Publisher · View at Google Scholar
  23. N. Thavandiran, N. Dubois, A. Mikryukov et al., “Design and formulation of functional pluripotent stem cell-derived cardiac microtissues,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 49, pp. E4698–E4707, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Mathur, P. Loskill, K. Shao et al., “Human iPSC-based cardiac microphysiological system for drug screening applications,” Scientific Reports, vol. 5, article 8883, 2015. View at Publisher · View at Google Scholar
  25. A. Marsano, C. Conficconi, M. Lemme et al., “Beating heart on a chip: a novel microfluidic platform to generate functional 3D cardiac microtissues,” Lab Chip, vol. 16, no. 3, pp. 599–610, 2016. View at Publisher · View at Google Scholar
  26. K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Yu, M. A. Vodyanik, K. Smuga-Otto et al., “Induced pluripotent stem cell lines derived from human somatic cells,” Science, vol. 318, no. 5858, pp. 1917–1920, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. B.-K. Chou and L. Cheng, “And then there were none: no need for pluripotency factors to induce reprogramming,” Cell Stem Cell, vol. 13, no. 3, pp. 261–262, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. J. T. Dimos, K. T. Rodolfa, K. K. Niakan et al., “Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons,” Science, vol. 321, no. 5893, pp. 1218–1221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Zhang, G. F. Wilson, A. G. Soerens et al., “Functional cardiomyocytes derived from human induced pluripotent stem cells,” Circulation Research, vol. 104, no. 4, pp. e30–e41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Taura, M. Sone, K. Homma et al., “Induction and isolation of vascular cells from human induced pluripotent stem cells —brief report,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 7, pp. 1100–1103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. T.-H. Lee, S.-H. Song, K. L. Kim et al., “Functional recapitulation of smooth muscle cells via induced pluripotent stem cells from human aortic smooth muscle cells,” Circulation Research, vol. 106, no. 1, pp. 120–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. R. M. Guzzo, J. Gibson, R.-H. Xu, F. Y. Lee, and H. Drissi, “Efficient differentiation of human iPSC-derived mesenchymal stem cells to chondroprogenitor cells,” Journal of Cellular Biochemistry, vol. 114, no. 2, pp. 480–490, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Zhang, W. Jiang, M. Liu et al., “Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells,” Cell Research, vol. 19, no. 4, pp. 429–438, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Song, J. Cai, Y. Liu et al., “Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells,” Cell Research, vol. 19, no. 11, pp. 1233–1242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Sadahiro, S. Yamanaka, and M. Ieda, “Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications,” Circulation Research, vol. 116, no. 8, pp. 1378–1391, 2015. View at Publisher · View at Google Scholar
  37. T. Zhou, C. Benda, S. Dunzinger et al., “Generation of human induced pluripotent stem cells from urine samples,” Nature Protocols, vol. 7, no. 12, pp. 2080–2089, 2012. View at Publisher · View at Google Scholar
  38. R. Mohseni, A. Shoae-Hassani, and J. Verdi, “Reprogramming of endometrial adult stromal cells in the presence of a ROCK inhibitor, thiazovivin, could obtain more efficient iPSCs,” Cell Biology International, vol. 39, no. 5, pp. 515–518, 2015. View at Publisher · View at Google Scholar
  39. C. Miere, L. Devito, and D. Ilic, “Sendai virus-based reprogramming of mesenchymal stromal/stem cells from umbilical cord wharton's jelly into induced pluripotent stem cells,” in Induced Pluripotent Stem (iPS) Cells: Methods and Protocols, vol. 1357 of Methods in Molecular Biology, pp. 33–44, Springer, Berlin, Germany, 2015. View at Publisher · View at Google Scholar
  40. T. Seki, S. Yuasa, M. Oda et al., “Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells,” Cell Stem Cell, vol. 7, no. 1, pp. 11–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. S. N. Dowey, X. Huang, B.-K. Chou, Z. Ye, and L. Cheng, “Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression,” Nature Protocols, vol. 7, no. 11, pp. 2013–2021, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Nishimura, M. Sano, M. Ohtaka et al., “Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming,” The Journal of Biological Chemistry, vol. 286, no. 6, pp. 4760–4771, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Miyoshi, H. Ishii, H. Nagano et al., “Reprogramming of mouse and human cells to pluripotency using mature microRNAs,” Cell Stem Cell, vol. 8, no. 6, pp. 633–638, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Kim, C.-H. Kim, J.-I. Moon et al., “Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins,” Cell Stem Cell, vol. 4, no. 6, pp. 472–476, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Zhou, S. Wu, J. Y. Joo et al., “Generation of induced pluripotent stem cells using recombinant proteins,” Cell Stem Cell, vol. 4, no. 5, pp. 381–384, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Rais, A. Zviran, S. Geula et al., “Deterministic direct reprogramming of somatic cells to pluripotency,” Nature, vol. 502, no. 7469, pp. 65–70, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Silva and A. Smith, “Capturing pluripotency,” Cell, vol. 132, no. 4, pp. 532–536, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. R. A. Young, “Control of the embryonic stem cell state,” Cell, vol. 144, no. 6, pp. 940–954, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Shu, C. Wu, Y. Wu et al., “Induction of pluripotency in mouse somatic cells with lineage specifiers,” Cell, vol. 153, no. 5, pp. 963–975, 2013. View at Publisher · View at Google Scholar
  50. N. Montserrat, E. Nivet, I. Sancho-Martinez et al., “Reprogramming of human fibroblasts to pluripotency with lineage specifiers,” Cell Stem Cell, vol. 13, no. 3, pp. 341–350, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Matsui, K. Zsebo, and B. L. M. Hogan, “Derivation of pluripotential embryonic stem cells from murine primordial germ cells in culture,” Cell, vol. 70, no. 5, pp. 841–847, 1992. View at Publisher · View at Google Scholar · View at Scopus
  52. J. L. Resnick, L. S. Bixler, L. Cheng, and P. J. Donovan, “Long-term proliferation of mouse primordial germ cells in culture,” Nature, vol. 359, no. 6395, pp. 550–551, 1992. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Hou, Y. Li, X. Zhang et al., “Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds,” Science, vol. 341, no. 6146, pp. 651–654, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Paull, A. Sevilla, H. Zhou et al., “Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells,” Nature Methods, vol. 12, no. 9, pp. 885–892, 2015. View at Publisher · View at Google Scholar
  55. M. Turner, S. Leslie, N. G. Martin et al., “Toward the development of a global induced pluripotent stem cell library,” Cell Stem Cell, vol. 13, no. 4, pp. 382–384, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Solomon, F. Pitossi, and M. S. Rao, “Banking on iPSC—is it doable and is it worthwhile,” Stem Cell Reviews and Reports, vol. 11, no. 1, pp. 1–10, 2015. View at Publisher · View at Google Scholar
  57. D. J. Pappas, P. Gourraud, C. Le Gall et al., “Proceedings: human leukocyte antigen haplo-homozygous induced pluripotent stem cell haplobank modeled after the california population: evaluating matching in a multiethnic and admixed population,” Stem Cells Translational Medicine, vol. 4, no. 5, pp. 413–418, 2015. View at Publisher · View at Google Scholar
  58. P. W. Burridge, E. Matsa, P. Shukla et al., “Chemically defined generation of human cardiomyocytes,” Nature Methods, vol. 11, pp. 855–860, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. C. L. Mummery, J. Zhang, E. S. Ng, D. A. Elliott, A. G. Elefanty, and T. J. Kamp, “Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview,” Circulation Research, vol. 111, no. 3, pp. 344–358, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Mummery, D. Ward-van Oostwaard, P. Doevendans et al., “Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells,” Circulation, vol. 107, no. 21, pp. 2733–2740, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. X. Lian, J. Zhang, S. M. Azarin et al., “Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions,” Nature Protocols, vol. 8, no. 1, pp. 162–175, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Xin, E. N. Olson, and R. Bassel-Duby, “Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair,” Nature Reviews Molecular Cell Biology, vol. 14, no. 8, pp. 529–541, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Tohyama, F. Hattori, M. Sano et al., “Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes,” Cell Stem Cell, vol. 12, no. 1, pp. 127–137, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. I. Huber, I. Itzhaki, O. Caspi et al., “Identification and selection of cardiomyocytes during human embryonic stem cell differentiation,” The FASEB Journal, vol. 21, no. 10, pp. 2551–2563, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. Q. Zhang, J. Jiang, P. Han et al., “Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals,” Cell Research, vol. 21, no. 4, pp. 579–587, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. X. Yang, L. Pabon, and C. E. Murry, “Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes,” Circulation Research, vol. 114, no. 3, pp. 511–523, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Ieda, J.-D. Fu, P. Delgado-Olguin et al., “Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors,” Cell, vol. 142, no. 3, pp. 375–386, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. Y.-J. Nam, K. Song, X. Luo et al., “Reprogramming of human fibroblasts toward a cardiac fate,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 14, pp. 5588–5593, 2013. View at Publisher · View at Google Scholar
  69. R. Wada, N. Muraoka, K. Inagawa et al., “Induction of human cardiomyocyte-like cells from fibroblasts by defined factors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 31, pp. 12667–12672, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. J.-D. Fu, N. R. Stone, L. Liu et al., “Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state,” Stem Cell Reports, vol. 1, no. 3, pp. 235–247, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. J. X. Chen, M. Krane, M.-A. Deutsch et al., “Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5.,” Circulation Research, vol. 111, no. 1, pp. 50–55, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. D. Srivastava and M. Ieda, “Critical factors for cardiac reprogramming,” Circulation Research, vol. 111, no. 1, pp. 5–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. S. A. Morris, P. Cahan, H. Li et al., “Dissecting engineered cell types and enhancing cell fate conversion via CellNet,” Cell, vol. 158, no. 4, pp. 889–902, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Moretti, M. Bellin, A. Welling et al., “Patient-specific induced pluripotent stem-cell models for long-QT syndrome,” The New England Journal of Medicine, vol. 363, no. 15, pp. 1397–1409, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Ma, L. Guo, S. J. Fiene et al., “High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 301, no. 5, pp. H2006–H2017, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. A. L. Lahti, V. J. Kujala, H. Chapman et al., “Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture,” Disease Models and Mechanisms, vol. 5, no. 2, pp. 220–230, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. I. Itzhaki, L. Maizels, I. Huber et al., “Modelling the long QT syndrome with induced pluripotent stem cells,” Nature, vol. 471, no. 7337, pp. 225–229, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. E. Dick, D. Rajamohan, J. Ronksley, and C. Denning, “Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening,” Biochemical Society Transactions, vol. 38, no. 4, pp. 1037–1045, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. Y.-K. Lee, K.-M. Ng, W.-H. Lai et al., “Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes,” Stem Cell Reviews and Reports, vol. 7, no. 4, pp. 976–986, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Novak, L. Barad, N. Zeevi-Levin et al., “Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation,” Journal of Cellular and Molecular Medicine, vol. 16, no. 3, pp. 468–482, 2012. View at Publisher · View at Google Scholar
  81. M. Hoekstra, C. L. Mummery, A. A. M. Wilde, C. R. Bezzina, and A. O. Verkerk, “Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias,” Frontiers in Physiology, vol. 3, article 346, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. B. C. Knollmann, “Induced pluripotent stem cell-derived cardiomyocytes: boutique science or valuable arrhythmia model?” Circulation Research, vol. 112, no. 6, pp. 969–976, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. N. M. Mordwinkin, P. W. Burridge, and J. C. Wu, “A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards,” Journal of Cardiovascular Translational Research, vol. 6, no. 1, pp. 22–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Sinnecker, A. Goedel, K.-L. Laugwitz, and A. Moretti, “Induced pluripotent stem cell-derived cardiomyocytes: a versatile tool for arrhythmia research,” Circulation Research, vol. 112, no. 6, pp. 961–968, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. S. G. M. Uzel, A. Pavesi, and R. D. Kamm, “Microfabrication and microfluidics for muscle tissue models,” Progress in Biophysics and Molecular Biology, vol. 115, no. 2-3, pp. 279–293, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Kofidis, P. Akhyari, J. Boublik et al., “In vitro engineering of heart muscle: artificial myocardial tissue,” The Journal of Thoracic and Cardiovascular Surgery, vol. 124, no. 1, pp. 63–69, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. C. A. Powell, B. L. Smiley, J. Mills, and H. H. Vandenburgh, “Mechanical stimulation improves tissue-engineered human skeletal muscle,” The American Journal of Physiology—Cell Physiology, vol. 283, no. 5, pp. C1557–C1565, 2002. View at Publisher · View at Google Scholar · View at Scopus
  88. W.-H. Zimmermann, I. Melnychenko, G. Wasmeier et al., “Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts,” Nature Medicine, vol. 12, no. 4, pp. 452–458, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Okano, S. Satoh, T. Oka, and T. Matsuda, “Tissue engineering of skeletal muscle: highly dense, highly oriented hybrid muscular tissues biomimicking native tissues,” ASAIO Journal, vol. 43, no. 5, pp. M749–M753, 1997. View at Publisher · View at Google Scholar · View at Scopus
  90. W.-H. Zimmermann, K. Schneiderbanger, P. Schubert et al., “Tissue engineering of a differentiated cardiac muscle construct,” Circulation Research, vol. 90, no. 2, pp. 223–230, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Hansen, A. Eder, M. Bönstrup et al., “Development of a drug screening platform based on engineered heart tissue,” Circulation Research, vol. 107, no. 1, pp. 35–44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Zhao, C. S. Chen, and D. H. Reich, “Force-driven evolution of mesoscale structure in engineered 3D microtissues and the modulation of tissue stiffening,” Biomaterials, vol. 35, no. 19, pp. 5056–5064, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. N. L. Tulloch, V. Muskheli, M. V. Razumova et al., “Growth of engineered human myocardium with mechanical loading and vascular coculture,” Circulation Research, vol. 109, no. 1, pp. 47–59, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Schaaf, A. Shibamiya, M. Mewe et al., “Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology,” PLoS ONE, vol. 6, no. 10, Article ID e26397, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. S. S. Nunes, J. W. Miklas, J. Liu et al., “Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes,” Nature Methods, vol. 10, no. 8, pp. 781–787, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. J. W. Miklas, S. S. Nunes, A. Sofla et al., “Bioreactor for modulation of cardiac microtissue phenotype by combined static stretch and electrical stimulation,” Biofabrication, vol. 6, no. 2, Article ID 024113, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. A. F. G. Godier-Furnémont, M. Tiburcy, E. Wagner et al., “Physiologic force-frequency response in engineered heart muscle by electromechanical stimulation,” Biomaterials, vol. 60, pp. 82–91, 2015. View at Publisher · View at Google Scholar
  98. C. M. Howard and T. A. Baudino, “Dynamic cell-cell and cell-ECM interactions in the heart,” Journal of Molecular and Cellular Cardiology, vol. 70, pp. 19–26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Ieda, “Heart development and regeneration via cellular interaction and reprogramming,” The Keio Journal of Medicine, vol. 62, no. 4, pp. 99–106, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. T. A. Baudino, A. McFadden, C. Fix, J. Hastings, R. Price, and T. K. Borg, “Cell patterning: interaction of cardiac myocytes and fibroblasts in three-dimensional culture,” Microscopy and Microanalysis, vol. 14, no. 2, pp. 117–125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. J. W. Nichol, G. C. Engelmayr Jr., M. Cheng, and L. E. Freed, “Co-culture induces alignment in engineered cardiac constructs via MMP-2 expression,” Biochemical and Biophysical Research Communications, vol. 373, no. 3, pp. 360–365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. H. Saini, A. Navaei, A. Van Putten, and M. Nikkhah, “3D cardiac microtissues encapsulated with the co-culture of cardiomyocytes and cardiac fibroblasts,” Advanced Healthcare Materials, vol. 4, no. 13, pp. 1961–1971, 2015. View at Publisher · View at Google Scholar
  103. A. Takeuchi, S. Nakafutami, H. Tani et al., “Device for co-culture of sympathetic neurons and cardiomyocytes using microfabrication,” Lab on a Chip, vol. 11, no. 13, pp. 2268–2275, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Takeuchi, K. Shimba, M. Mori et al., “Sympathetic neurons modulate the beat rate of pluripotent cell-derived cardiomyocytes in vitro,” Integrative Biology, vol. 4, no. 12, pp. 1532–1539, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. A. Takeuchi, K. Shimba, Y. Takayama et al., “Microfabricated device for co-culture of sympathetic neuron and iPS-derived cardiomyocytes,” in Proceedings of the 35th IEEE Annual International Conference of the Engineering in Medicine and Biology Society (EMBC '13), pp. 3817–3820, IEEE, Osaka, Japan, July 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. K. Miwa, J.-K. Lee, Y. Takagishi et al., “Axon guidance of sympathetic neurons to cardiomyocytes by glial cell line-derived neurotrophic factor (GDNF),” PLoS ONE, vol. 8, no. 7, Article ID e65202, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. D. L. Brutsaert, “Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity,” Physiological Reviews, vol. 83, no. 1, pp. 59–115, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. D. A. Narmoneva, R. Vukmirovic, M. E. Davis, R. D. Kamm, and R. T. Lee, “Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration,” Circulation, vol. 110, no. 8, pp. 962–968, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. I. Vollert, M. Seiffert, J. Bachmair et al., “In vitro perfusion of engineered heart tissue through endothelialized channels,” Tissue Engineering—Part A, vol. 20, no. 3-4, pp. 854–863, 2014. View at Publisher · View at Google Scholar · View at Scopus
  110. L. L. Y. Chiu, M. Montgomery, Y. Liang, H. Liu, and M. Radisic, “Perfusable branching microvessel bed for vascularization of engineered tissues,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 50, pp. E3414–E3423, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. L. Ghasemi-Mobarakeh, M. P. Prabhakaran, M. Nematollahi, K. Karbalaie, S. Ramakrishna, and M. H. Nasr-Esfahani, “Embryonic stem cell differentiation to cardiomyocytes on nanostructured scaffolds for myocardial tissue regeneration,” International Journal of Polymeric Materials and Polymeric Biomaterials, vol. 63, no. 5, pp. 240–245, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. S. Battista, D. Guarnieri, C. Borselli et al., “The effect of matrix composition of 3D constructs on embryonic stem cell differentiation,” Biomaterials, vol. 26, no. 31, pp. 6194–6207, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. E. Serena, E. Figallo, N. Tandon et al., “Electrical stimulation of human embryonic stem cells: cardiac differentiation and the generation of reactive oxygen species,” Experimental Cell Research, vol. 315, no. 20, pp. 3611–3619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. N. Tandon, A. Marsano, R. Maidhof et al., “Surface-patterned electrode bioreactor for electrical stimulation,” Lab on a Chip, vol. 10, no. 6, pp. 692–700, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. A. Pavesi, G. Adriani, M. Rasponi, I. K. Zervantonakis, G. B. Fiore, and R. D. Kamm, “Controlled electromechanical cell stimulation on-a-chip,” Scientific Reports, vol. 5, Article ID 11800, 2015. View at Publisher · View at Google Scholar
  116. P. Perel, I. Roberts, E. Sena et al., “Comparison of treatment effects between animal experiments and clinical trials: systematic review,” British Medical Journal, vol. 334, no. 7586, pp. 197–200, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Mollova, K. Bersell, S. Walsh et al., “Cardiomyocyte proliferation contributes to heart growth in young humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 4, pp. 1446–1451, 2013. View at Publisher · View at Google Scholar
  118. P. J. Kannankeril and D. M. Roden, “Drug-induced long QT and torsade de pointes: recent advances,” Current Opinion in Cardiology, vol. 22, no. 1, pp. 39–43, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. L. Carlsson, “In vitro and in vivo models for testing arrhythmogenesis in drugs,” Journal of Internal Medicine, vol. 259, no. 1, pp. 70–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. N. Sun, M. Yazawa, J. Liu et al., “Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy,” Science Translational Medicine, vol. 4, no. 130, Article ID 130ra47, 2012. View at Publisher · View at Google Scholar
  121. F. Lan, A. S. Lee, P. Liang et al., “Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells,” Cell Stem Cell, vol. 12, no. 1, pp. 101–113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. D. Ma, H. Wei, J. Lu et al., “Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy,” European Heart Journal, vol. 34, no. 15, pp. 1122–1133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. O. Caspi, I. Huber, A. Gepstein et al., “Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells,” Circulation: Cardiovascular Genetics, vol. 6, no. 6, pp. 557–568, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. C. Kim, J. Wong, J. Wen et al., “Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs,” Nature, vol. 494, no. 7435, pp. 105–110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  125. F. Djouadi, Y. Lecarpentier, J.-L. Hébert, P. Charron, J. Bastin, and C. Coirault, “A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy,” Cardiovascular Research, vol. 84, no. 1, pp. 83–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. E. Matsa, D. Rajamohan, E. Dick et al., “Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation,” European Heart Journal, vol. 32, no. 8, pp. 952–962, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. C. I. Spencer, S. Baba, K. Nakamura et al., “Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia,” Stem Cell Reports, vol. 3, no. 2, pp. 269–281, 2014. View at Publisher · View at Google Scholar
  128. R. P. Davis, S. Casini, C. W. Van Den Berg et al., “Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease,” Circulation, vol. 125, no. 25, pp. 3079–3091, 2012. View at Publisher · View at Google Scholar · View at Scopus
  129. A. Fatima, S. Kaifeng, S. Dittmann et al., “The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients,” PLoS ONE, vol. 8, no. 12, Article ID e83005, 2013. View at Publisher · View at Google Scholar · View at Scopus
  130. M. Yazawa, B. Hsueh, X. Jia et al., “Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome,” Nature, vol. 471, no. 7337, pp. 230–236, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. A. Fatima, G. Xu, K. Shao et al., “In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells,” Cellular Physiology and Biochemistry, vol. 28, no. 4, pp. 579–592, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. C. B. Jung, A. Moretti, M. Mederos y Schnitzler et al., “Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia,” The EMBO Molecular Medicine, vol. 4, no. 3, pp. 180–191, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. X. Carvajal-Vergara, A. Sevilla, S. L. Dsouza et al., “Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome,” Nature, vol. 465, no. 7299, pp. 808–812, 2010. View at Publisher · View at Google Scholar · View at Scopus
  134. Y. Jiang, S. Habibollah, K. Tilgner et al., “An induced pluripotent stem cell model of hypoplastic left heart syndrome (HLHS) reveals multiple expression and functional differences in HLHS-derived cardiac myocytes,” Stem Cells Translational Medicine, vol. 3, no. 4, pp. 416–423, 2014. View at Publisher · View at Google Scholar · View at Scopus
  135. J. Finsterer and L. Cripe, “Treatment of dystrophin cardiomyopathies,” Nature Reviews Cardiology, vol. 11, no. 3, pp. 168–179, 2014. View at Publisher · View at Google Scholar · View at Scopus
  136. E. Dick, S. Kalra, D. Anderson et al., “Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations,” Stem Cells and Development, vol. 22, no. 20, pp. 2714–2724, 2013. View at Publisher · View at Google Scholar
  137. S. Zatti, S. Martewicz, E. Serena et al., “Complete restoration of multiple dystrophin isoforms in genetically corrected Duchenne muscular dystrophy patient–derived cardiomyocytes,” Molecular Therapy—Methods & Clinical Development, vol. 1, 2014. View at Publisher · View at Google Scholar
  138. X. Guan, D. L. Mack, C. M. Moreno et al., “Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery,” Stem Cell Research, vol. 12, no. 2, pp. 467–480, 2014. View at Publisher · View at Google Scholar · View at Scopus
  139. B. Lin, Y. Li, L. Han et al., “Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy,” Disease Models & Mechanisms, vol. 8, no. 5, pp. 457–466, 2015. View at Publisher · View at Google Scholar
  140. J. Y. Wen, C. Wei, K. Shah, J. Wong, C. Wang, and H. V. Chen, “Maturation-based model of arrhythmogenic right ventricular dysplasia using patient-specific induced pluripotent stem cells,” Circulation Journal, vol. 79, no. 7, pp. 1402–1408, 2015. View at Publisher · View at Google Scholar
  141. B. T. Darras, D. T. Miller, and D. K. Urion, “Dystrophinopathies,” in GeneReviews(R), R. A. Pagon, M. P. Adam, H. H. Ardinger et al., Eds., University of Washington, Seattle, Wash, USA, 1993. View at Google Scholar
  142. A. Goyenvalle, G. Griffith, A. Babbs et al., “Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers,” Nature Medicine, vol. 21, no. 3, pp. 270–275, 2015. View at Publisher · View at Google Scholar · View at Scopus
  143. H. L. Li, N. Fujimoto, N. Sasakawa et al., “Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9,” Stem Cell Reports, vol. 4, no. 1, pp. 143–154, 2015. View at Publisher · View at Google Scholar · View at Scopus
  144. K. G. Chen, B. S. Mallon, R. D. G. McKay, and P. G. Robey, “Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics,” Cell Stem Cell, vol. 14, no. 1, pp. 13–26, 2014. View at Publisher · View at Google Scholar · View at Scopus